BUZZ - Sandsera Engineering stock price hits a record high in India; Goldman Sachs raises target price boosted by the global chip industry
路透社2026/09/22 05:31September 22 - ** Precision parts manufacturer Sansera Engineering (stock code: SASE.NS) shares surged as much as 4.95%, reaching a record high of 4,509.80 rupees
** The stock is poised to rise for a fifth straight session
** Goldman Sachs Research noted that global semiconductor equipment manufacturers Applied Materials (AMAT.O) and LAM Research (LRCX.O) are investing in India to build a local supplier ecosystem, which is expected to drive SASE’s high-margin “advanced design systems” components supply business
** The brokerage maintains a “Buy” rating on the stock and has raised its target price from 4,500 rupees to 4,990 rupees (a record market high)
** Seven out of twelve analysts rate the stock “Buy” or higher, with a median target price of 4,185 rupees—data compiled by LSEG
** Year to date, the share price has surged 169.05%
(To assist non-English speakers, Reuters provides its reports with automated translations into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely to aid readers. Reuters accepts no liability for any harm or losses resulting from use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).